Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03123588
Study type Interventional
Source Incyte Corporation
Contact
Status Terminated
Phase Phase 2
Start date November 14, 2017
Completion date August 3, 2020

See also
  Status Clinical Trial Phase
Completed NCT01348490 - Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) Phase 2
Completed NCT02252159 - Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Completed NCT01633372 - An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis Phase 2
Completed NCT03144687 - A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Phase 2
Terminated NCT02718300 - A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Phase 2
Completed NCT02953704 - Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
Completed NCT00952289 - COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Phase 3
Active, not recruiting NCT03011372 - A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) Phase 2